FDA
-
-
-
-
-
-
-
Aurinia defends LUPKYNIS after FDA official retracts LinkedIn post
-
-
-
-
-
-
-
Aurinia Announces Positive Results from Phase 1 Study of Aritinercept (AUR200)
-
-
-
-
-
-
-
Aurinia Pharmaceuticals Reports Financial Results for the Three and Twelve Months Ended December 31, 2024 and Provides Update on Recent Corporate Progress
-
-
-
-
-
-
-
Aurinia Pharmaceuticals Reports Third Quarter and Nine Months 2024 Financial and Operational Results, Announces Strategic Restructuring to Sharpen Focus on Continued LUPKYNIS® Growth and AUR200 Devel
-
-
-
-
-
-
-
Aurinia Pharmaceuticals (AUPH) Announces Board Restructuring
-
-
-
-
-
-
-
Aurinia Pharmaceuticals Reports Second Quarter and Six Months 2024 Financial and Operational Results
-
-
-
-
-
-
-
Aurinia Provides Update on Proxy Statement
-
312,667 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

